Literature DB >> 13011049

Agranulocytosis following use of phenylbutazone (butazolidin).

E BERSHOF, A C OXMAN.   

Abstract

Entities:  

Keywords:  ACTH/therapeutic use; AGRANULOCYTOSIS/etiology and pathogenesis; ANALGESICS/toxicity

Mesh：

Substances：

Year:  1953        PMID： 13011049     DOI： 10.1001/jama.1953.02940070023007b

Source DB:  PubMed          Journal:  J Am Med Assoc        ISSN： 0002-9955


× No keyword cloud information.
  6 in total

1.  Toxic effects of phenylbutazone.

Authors:  J R NASSIM; T PILKINGTON
Journal:  Br Med J       Date:  1953-06-13

2.  Phenylbutazone and renal function.

Authors:  B M JOHNSON; I M LARKIN
Journal:  Br Med J       Date:  1954-11-06

3.  Clinical studies of phenylbutazone (butazolidin) and butapyrin (irgapyrin) in rheumatoid arthritis, rheumatoid spondylitis, and gout.

Authors:  E G KIDD; K C BOYCE; R H FREYBERG
Journal:  Ann Rheum Dis       Date:  1953-03       Impact factor: 19.103

4.  Phenylbutazone: an evaluation of its use.

Authors:  W G SNOW
Journal:  Calif Med       Date:  1953-09

5.  HEMATOLOGICAL COMPLICATIONS OF PHENYLBUTAZONE THERAPY: REVIEW OF THE LITERATURE AND REPORT OF TWO CASES.

Authors:  D D MCCARTHY; T M CHALMERS
Journal:  Can Med Assoc J       Date:  1964-05-02       Impact factor: 8.262

6.  Clinical experience with phenylbutazone (Butazolidin).

Authors:  J B FRAIN; J E MORRIS
Journal:  Can Med Assoc J       Date:  1954-11       Impact factor: 8.262
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.